Welcome to our dedicated page for Heartflow SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Heartflow's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Heartflow's regulatory disclosures and financial reporting.
HeartFlow, Inc. (HTFL) reported interim financial and operational disclosures reflecting a recent reverse stock split, significant financing activity and continuing operating losses. The company completed an IPO that raised approximately $364.2 million gross proceeds (before underwriting discounts and estimated offering expenses). As of June 30, 2025, cash and cash equivalents were $80.2 million versus $51.4 million at December 31, 2024, and the company had an accumulated deficit of approximately $1.0 billion. The company issued 2025 Convertible Notes totaling $98.3 million with embedded derivative features and maintains a 2024 Term Loan with an effective interest rate of 15.2% as of June 30, 2025. The 2024 Credit Agreement contains collateral, liquidity and trailing net sales covenants, including a minimum liquidity requirement reduced to $15.0 million and a rising minimum twelve-month net sales covenant up to $110.0 million. Management states that, together with expected customer revenue and IPO proceeds, available liquidity is sufficient to fund planned operations for at least the next 12 months from the date the condensed consolidated financial statements were available to be issued.
HealthCor-related entities reported acquisitions of Heartflow, Inc. (HTFL) securities on 08/11/2025 recorded in a joint Form 4 filing. The filing shows HealthCor Partners Fund, L.P. acquired 1,248,939 common shares (as-converted from Series C preferred), HealthCor Partners Fund II, L.P. acquired 833,075 common shares (as-converted), and HCPCIV 1, LLC acquired 4,615,542 common shares (as-converted). Multiple preferred series and a convertible promissory note were reported as automatically converted into specified common share amounts immediately prior to Heartflow's IPO closing. Reporting signatures are dated 08/22/2025.
HealthCor-affiliated entities reported initial beneficial ownership in Heartflow, Inc. (HTFL). Multiple HealthCor funds and affiliates each hold various series of convertible preferred stock and a convertible promissory note that will convert into Heartflow common stock upon the closing of Heartflow's initial public offering. Conversion ratios after a 1-for-2.92 reverse split are disclosed for Series C, D, E, F and F-1 preferred stock and a conversion mechanism is disclosed for the promissory note (80% of IPO price, subject to a $2.0 billion valuation cap). HealthCor Partners Management, L.P. is the investment manager with voting and investment discretion and disclaims direct beneficial ownership except for pecuniary interests.
Bain Capital Life Sciences Investors, LLC and affiliated entities reported conversions of pre-IPO securities into Heartflow, Inc. common stock on 08/11/2025. The Issuer's Series F Preferred Stock converted on a 0.342466:1 basis into 12,014,234 common shares. A Subordinated Convertible Promissory Note with principal $6,595,648.51 converted into 433,924 common shares at a stated conversion price of $15.2. Following these transactions, the reporting group beneficially owned 12,448,158 common shares. The filings identify the reporting persons as directors and 10% owners and disclose an indirect ownership chain through several Bain Capital entities, with customary disclaimers about beneficial ownership.
FAQ
What is the current stock price of Heartflow (HTFL)?
What is the market cap of Heartflow (HTFL)?
